INFECTIONS IN OCRELIZUMAB RECIPIENTS FROM PHASE III STUDIES

被引：0

作者：

Gavin, Giovannoni ^{[1
]}

Hans-Peter, Hartung ^{[2
]}

Giancarlo, Comi ^{[3
]}

Jerome, de Seze ^{[4
]}

Bernhard, Hemmer ^{[5
]}

Ludwig, Kappos ^{[6
]}

Xavier, Montalban ^{[7
]}

Krzysztof, Selmaj ^{[8
]}

Nicole, Mairon ^{[9
]}

Jerry, Wolinsky ^{[10
]}

机构：

[1] Queen Mary Univ London, London, England

[2] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany

[3] Univ Vita Salute San Raffaele, Milan, Italy

[4] Univ Hosp Strasbourg, Strasbourg, France

[5] Tech Univ Munich, Munich, Germany

[6] Univ Hosp Basel, Basel, Switzerland

[7] Univ Toronto, Toronto, ON, Canada

[8] Med Univ Lodz, Lodz, Poland

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] UTHealth, McGovern Med Sch, Houston, TX USA

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2018年 / 89卷 / 10期

关键词：

D O I：

10.1136/jnnp-2018-ABN.92

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

WED 187

引用

页数：2

共 50 条

[31] Experimental studies of the nasopharyngeal secretions from influenza patients. III. Studies of the concurrent infections.
Olitsky, PK
Gates, FL
JOURNAL OF EXPERIMENTAL MEDICINE, 1921, 33 (03): : 373 - U18
[32] Phase rule studies on the proteins III
Bancroft, WD
Barnett, CE
JOURNAL OF PHYSICAL CHEMISTRY, 1930, 34 (06): : 1217 - 1253
[33] On the importance of phase III studies - Comment
Krauth, J
PHARMACOPSYCHIATRY, 1996, 29 (04) : 142 - 143
[34] Predicting success in phase III studies from phase II results: A new paradigm is needed
Leff, Richard
Andrews, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3653 - 3654
[35] Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
Hartung, H. -P.
Arnold, D. L.
Bar-Or, A.
Comi, G.
de Seze, J.
Giovannoni, G.
Hauser, S. L.
Hemmer, B.
Kappos, L.
Lublin, F.
Montalban, X.
Rammohan, K. W.
Selmaj, K.
Traboulsee, A.
Chin, P.
Li, C.
Mairon, N.
Napieralski, J.
Wolinsky, J.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 658 - 659
[36] Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies
Lublin, F.
Arnold, D.
Bar-or, A.
Comi, G.
Hartung, H. -P.
Hauser, S.
Selmaj, K.
Traboulsee, A.
Chin, P.
Fontoura, P.
Garren, H.
Klingelschmitt, G.
Masterman, D.
Kappos, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 402 - 402
[37] Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
Rammohan, Kottil W.
Hartung, Hans-Peter
Arnold, Douglas L.
Bar-Or, Amit
Comi, Giancarlo
de Seze, Jerome
Giovannoni, Gavin
Hauser, Stephen L.
Hemmer, Bernhard
Kappos, Ludwig
Lublin, Fred
Montalban, Xavier
Selmaj, Krzysztof
Traboulsee, Anthony
Chin, Peter
Li, Carrie
Mairon, Nicole
Napieralski, Julie
Wolinsky, Jerry
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 31 - 32
[38] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Fox, Edward J.
Markowitz, Clyde
Applebee, Angela
Montalban, Xavier
Wolinsky, Jerry S.
Belachew, Sihbeshih
Fiore, Damian
Pei, Jinglan
Musch, Bruno
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870
[39] Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis
Hauser, S.
Comi, G.
Hartung, H. -P.
Selmaj, K.
Traboulsee, A.
Bar-Or, A.
Arnold, D.
Klingelschmitt, G.
Leppert, D.
Kakarieka, A.
Lublin, F.
Garren, H.
Kappos, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 752 - 752
[40] A Phase III, open-label study to evaluate the effect of ocrelizumab on immune responses in patients with relapsing MS
Millar, L.
Li, C.
Bennett, H.
Garren, H.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 407 - 407

← 1 2 3 4 5 →